MedTrace Logo

Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers

NCT01471704 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-06-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the potential for a pharmacokinetic (PK) drug-drug interaction between INX-08189 and extended release verapamil hydrochloride (verapamil HCL ER).

Conditions

  • Healthy

Interventions

DRUG

INX-08189 50 mg

Study Day 0: Single 50 mg dose of INX-08189 in the morning

DRUG

240 mg verapamil HCL ER

Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning

DRUG

50 mg dose of INX-08189 and 240 mg verapamil HCL ER

Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning

Sponsors & Collaborators

Principal Investigators

  • Ralph Campaneria, MD

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01471704 on ClinicalTrials.gov